Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apollomics Inc. - Class A Ordinary Shares (NQ: APLM )

0.1612 +0.0152 (+10.41%)
Streaming Delayed Price Updated: 10:29 AM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 512,473
Open 0.1459
Bid (Size) 0.1600 (51)
Ask (Size) 0.1612 (1)
Prev. Close 0.1460
Today's Range 0.1450 - 0.1620
52wk Range 0.1053 - 3.710
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
Vebreltinib is efficacious in both treatment naïve and previously treated patients with NSCLC with METex14 skipping, and regardless of co-occurring MET amplification 
From Apollomics Inc.
Via GlobeNewswire

Performance

YTD
-82.46%
-82.46%
1 Month
+42.65%
+42.65%
3 Month
-16.13%
-16.13%
6 Month
-76.01%
-76.01%
1 Year
-95.52%
-95.52%

More News

Read More
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Apollomics Inc.
Via GlobeNewswire
What's Going On With Apollomics (APLM) Stock Exploding Higher?
Via Benzinga
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
From Apollomics Inc.
Via GlobeNewswire
S&P 500 Gains 1%; Home Depot Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Penny Stock Apollomics Trading Higher On Tuesday?
Via Benzinga
Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
Via Benzinga
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
From Apollomics Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Why Chuy's Holdings Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Apollomics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Apollomics Announces Presentation at the 2024 BIO International Convention
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Private Placement Financing and Addition to Board of Directors
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
From Apollomics Inc.
Via GlobeNewswire
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Apollomics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
From Apollomics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
From Apollomics Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.